Loading
A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Beijing Gene Key Life Technology Co., Ltd, active and no longer recruiting.
A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07777211 by Beijing Gene Key Life Technology Co., Ltd, with 52 participants enrolled, started 2025-08-14 and due to reach its primary completion in 2027-03-31. Interventions recorded: GKL-006 injection and Nab-paclitaxel and Gemcitabine.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Beijing Gene Key Life Technology and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy and the tag pipeline.